After Hours
$
69.00
Change
-1.65 -2.34%
Volume
Volume 988
Mar 4, 2021, 7:10 p.m.
Quotes are delayed by 20 min
Previous close
$ 76.17
$ 70.65
Change
-5.52 -7.25%
Day low
Day high
$69.32
$75.13

52 week low
52 week high
$25.01
$98.39

Market cap
$4.45B
Average volume
496,064
P/E ratio
6.37
Rev. per Employee
$3.74M
EPS
11.09
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on SAGE
-
Sage Therapeutics downgraded to neutral from buy at Mizuho
- Tomi Kilgore
-
Biogen’s Alzheimer’s Drug Faces a Big Test
- Barron's Online
-
Sage Therapeutics downgraded to market perform at BMO Capital
- Tomi Kilgore
-
Stocks Close Higher on Stimulus Hopes, Manufacturing Data
- Barron's Online
-
Zoom Stock Falls as News From China Lifts the Dow.
- Barron's Online
-
Sage Therapeutics downgraded to market perform from outperform at Raymond James
- Tomi Kilgore
-
S&P 500, Nasdaq book record closes on Black Friday
- Mark DeCambre
-
S&P 500 and Nasdaq Close at Records as Tech Stocks Outperform
- Barron's Online
-
Sage Gets $3 Billion Endorsement of Its Depression Drugs From Biogen
- Barron's Online
-
Sage Soars, AstraZeneca Slips and the Dow Gets a Black Friday Bump
- Barron's Online
-
Sage Therapeutics shares soar 10% premarket after resuming trade following halt
- Ciara Linnane
-
Sage Therapeutics shares halted premarket for the news
- Ciara Linnane
-
Biogen and Sage Therapeutics to jointly develop therapies for depression and movement disorders
- Ciara Linnane
-
Sage Therapeutics to receive $1.525 bln in cash from Biogen as part of deal
- Ciara Linnane
-
Sage Therapeutics stock price target raised to $77 from $53 at Mizuho
- Tomi Kilgore
-
Sage Therapeutics upgraded to outperform from neutral at Wedbush
- Tomi Kilgore
-
Mylan Is Eager to Launch Rival Version of Biogen’s Biggest-Selling Drug
- Barron's Online
-
Sage Therapeutics downgraded to neutral from outperform at Wedbush
- Tomi Kilgore
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For February 26, 2018
- Benzinga.com
-
Cowen Raises Sage Value On New Phase 2 Trial Success
- Benzinga.com
Other News on SAGE
-
Premarket analyst action - healthcare
- Seeking Alpha
-
Why Did Mizuho Securities Downgrade SAGE Therapeutics’ Stock?
- SmarterAnalyst
-
Sage Therapeutics: Steady Recovery After Biogen Deal
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Sage Therapeutics EPS of $18.19
- Seeking Alpha
-
Notable earnings before Wednesday's open
- Seeking Alpha
-
Sage Therapeutics Q4 2020 Earnings Preview
- Seeking Alpha
-
Biogen upgraded to buy at Stifel on aducanumab optimism
- Seeking Alpha
-
Fundsmith Equity Fund Annual Letter 2020 To Shareholders
- Seeking Alpha
-
Sage Therapeutics downgraded at BMO citing valuation
- Seeking Alpha
- Loading more headlines...
Earnings Announcement
Press Releases on SAGE
-
Sage Therapeutics to Present at Upcoming Investor Conferences
- BusinessWire - BZX
-
Sage Therapeutics Announces the Appointment of Barry Greene as CEO
- BusinessWire - BZX
-
The Biotech Breakthrough Transforming Mental Health
- Financial News Media
-
The Biotech Breakthrough Transforming Mental Health
- PR Newswire - PRF
-
Savvy Companies Making Moves in Drug-Development Space
- NetworkNewsWire
-
Savvy Companies Making Moves in Drug-Development Space
- PR Newswire - PRF
-
Sage Therapeutics to Present at Upcoming November Investor Conferences
- BusinessWire - BZX
-
Sage Therapeutics Appoints Barry Greene to Board of Directors
- BusinessWire - BZX
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com